Chapter 111 of the General Laws, as appearing in the 2022 Official Edition, is hereby amended by inserting after section 244 the following section:-

Section 245. (a) As used in this section the following words shall, unless the context clearly requires otherwise, have the following meanings:-

“Estimated cost'', a projection of funds needed during a fiscal year for the purchase, storage and distribution of opioid antagonists.

''Opioid antagonist'', naloxone or any other drug approved by the federal Food and Drug Administration as a competitive narcotic antagonist used in the reversal of overdoses caused by opioids.

“Opioid antagonist distribution”,  the provision of opioid antagonists to healthcare facilities including, but not limited to:

(i)acute care hospitals;

(ii)emergency departments;

(iii)substance use disorder treatment facilities; and

(iv)community health centers

provided that, opioid antagonists shall be offered to a patient who has (i) a history of using opioids; (ii) been diagnosed with opioid use disorder; or (iii) experienced an opioid-related overdose.

“Substance use disorder treatment facilities”, a facility licensed or approved by the department or the department of mental health to offer treatment for substance use disorder, including, but not limited to: (i) withdrawal management services; (ii) clinical stabilization services; (iii) transitional support services; (iv) residential support services; (v) community behavioral health center services; (vi) office-based opioid or addiction treatment services; or (vii) inpatient or outpatient substance use disorder services.

(b) There shall be established in the commonwealth a separate trust fund to be known as the Naloxone Purchase Trust Fund to support a universal purchase system for opioid antagonist distribution in the commonwealth. The fund shall be expended to cover the costs of opioid antagonist distribution. The fund shall consist of all monies transferred from the executive office of health and human services pursuant to section 66 of chapter 118E, all money received as voluntary contributions to the fund, including but not limited to contributions from third party payers or third party administrators, as defined in section 1 of chapter 12C, and any interest earnings on such monies. The fund shall be maintained by the commissioner of the department or a designee. The monies shall be expended under the direction of the department, without prior appropriation, solely to cover opioid antagonist distribution program costs; provided, however, that the amount to be expended for storing and distributing opioid antagonists, if such costs are not covered by federal contribution, shall not exceed 10 per cent of the total amount of the fund expended for the purchase of naloxone needed for opioid agonist distribution in the commonwealth. The department may incur expenses and the comptroller may certify for payment amounts in anticipation of the most recent estimate of expected receipts, as certified by the secretary of administration and finance; provided, however, that no expenditure shall be made from the fund that shall cause the fund to be in deficit at the close of a fiscal year. Any balance in the fund at the close of a fiscal year shall be available for expenditure in subsequent fiscal years and shall not be transferred to any other fund or revert to the General Fund. The commissioner of the department or a designee shall annually report the amount of funds collected and any expenditures made from the fund to the house and senate committees on ways and means, the joint committee on public health and the joint committee on health care financing.

(c) The department may adopt rules and regulations as necessary to implement the universal purchase and distribution system under this chapter and other applicable state and federal laws.